Table 2.
Pharmaceutical companies pursuing CAR T cells
| Company | CAR-T name | Target | Disease | Trial phase |
|---|---|---|---|---|
| bluebird bio with Celgene | bb2121 | B-cell maturation antigen (BCMA) | Multiple myeloma | I |
| Cellectis with Pfizer | UCAR19 | CD19 | Pediatric B-cell acute lymphoblastic leukemia | I |
| Juno Therapeutics | JCAR017 | CD19 | B-cell non-Hodgkin lymphoma | I |
| Juno Therapeutics | JCAR023 | L1-CAM | Neuroblastoma | I |
| Juno Therapeutics | JCAR015 | CD19 | Acute lymphoblastic leukemia | II |
| Kite Pharma | KTE-C19 | CD19 | Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma | II |
| Novartis | CTL019 | CD19 | Acute lymphoblastic leukemia | II |
All information taken from Company Websites.